Novartis Pharmaceuticals UK LimitedUK Head OfficeFrimley Business Park FrimleyCamberley Surrey GU16 7SR
+44 1276 692255+44 1276 692508Monday - Friday,8:30 - 17:30
Novartis International AGInvestor RelationsP.O. BoxCH-4002 BaselSwitzerland
+41 61 324 79 firstname.lastname@example.org
Novartis UK Press OfficePress Office enquiries only
+44 1276 email@example.com
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
For enquiries contact
+44 1276 698 firstname.lastname@example.org
20 million people globally and around 900,000 people in the UK have heart failure. Learn more here about causes, symptoms and watch videos from people living with heart failure.
23 April 2015
Novartis is delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine (PIM) designation for its investigational medicine for patients with heart failure (HF) with reduced ejection fraction, LCZ696 (sacubitril/valsartan).
2 March 2015
Novartis announced that it has completed a series of transactions with GlaxoSmithKline plc (GSK), including the acquisition of certain oncology products and pipeline compounds from GSK, the creation of a world-leading consumer healthcare business through a joint venture that combines the two companies' consumer divisions, and the divestiture of the Novartis non-influenza Vaccines business to GSK.
27 January 2014
Novartis has announced the full year results for 2014.
Adverse event reporting
Product Information Leaflets (PILs) for patients
Summary of Product Characteristics (SPC) for Healthcare Professionals